Cetylpyridium Chloride (CPC) Based Chewing Gum and Gingivitis
NCT ID: NCT03219840
Last Updated: 2021-02-08
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
70 participants
INTERVENTIONAL
2017-10-18
2018-09-08
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety and Tolerability of Antiplaque Chewing Gum in a Gingivitis Population
NCT01877421
Clinical Effects of Two New Chlorhexidine Digluconate Formulations: 0.12% and 0.03%.
NCT02194023
Clinical and Microbiological Comparison of 0.12% CHX and 0.05% CHX+0.05%CPC Mouthwashes in TPS Patients
NCT06411522
Comparative Effects of Two Oral Antiseptics Used as an Adjuvant in the Treatment of Periodontitis
NCT06967402
Clinical Efficacy of the Combined Effect of Oral Irrigator and Chemicals (0.075% CPC)
NCT06607172
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
PREVENTION
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
CPC + Xylitol chewing gum, then Xylitol only chewing gum
Cetylpyridinium Chloride (CPC) 0.09% + Xylitol chewing gum and then Xylitol only chewing gum All subjects will be instructed to chew four times a day, for at least 60 seconds, after which they expectorated. Cetylpyridinium Chloride (CPC) 0.09% + Xylitol chewing gum will be used for the first 21 days, then there will be a washout period of 21 days, and finally Xylitol only chewing gum will be used for the last 21 days.
Cetylpyridinium Chloride (CPC) 0.09% + Xylitol chewing gum
All subjects will be instructed to chew four times a day, for at least 60 seconds, after which they expectorated.
Xylitol only chewing gum
All subjects will be instructed to chew four times a day, for at least 60 seconds, after which they expectorated.
Xylitol only chewing gum, then CPC + Xylitol chewing gum
Xylitol only chewing gum and then Cetylpyridinium Chloride (CPC) 0.09% + Xylitol chewing gum All subjects will be instructed to chew four times a day, for at least 60 seconds, after which they expectorated. Xylitol only chewing gum will be used for the first 21 days, then there will be a washout period of 21 days, and finally Cetylpyridinium Chloride (CPC) 0.09% + Xylitol chewing gum will be used for the last 21 days.
Cetylpyridinium Chloride (CPC) 0.09% + Xylitol chewing gum
All subjects will be instructed to chew four times a day, for at least 60 seconds, after which they expectorated.
Xylitol only chewing gum
All subjects will be instructed to chew four times a day, for at least 60 seconds, after which they expectorated.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Cetylpyridinium Chloride (CPC) 0.09% + Xylitol chewing gum
All subjects will be instructed to chew four times a day, for at least 60 seconds, after which they expectorated.
Xylitol only chewing gum
All subjects will be instructed to chew four times a day, for at least 60 seconds, after which they expectorated.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Be capable of giving informed consent themselves and are able and willing to participate in the study
* Patients willing to forgo any optional dental procedures during the study period, such as dental prophylaxis or teeth whitening
* Patients that regularly brush their teeth twice a day
Exclusion Criteria
* Patients taking long-term anti-microbial or anti-inflammatory drugs
* Patients unable or unwilling to provide informed consent
* Self-reported use of tobacco products
* Gross oral pathology, including widespread caries or chronic neglect, extensive restoration, pre-existing gross plaque or calculus, or soft or hard tissue tumor of the oral cavity
* Less than 26 teeth in the mouth
* Orthodontic appliances or removable partial dentures that will compromise the ability of the potential subject to participate in the study
* Periodontitis as indicated periodontal pockets greater than 5 millimeters on more than one site
* Inability to comply with assigned treatment regimen
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
CONFADENT Oral Technology, Kiss Industries LLC
UNKNOWN
The University of Texas Health Science Center, Houston
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Flavia Lakschevitz, DDS, PhD
Role: PRINCIPAL_INVESTIGATOR
The University of Texas Health Science Center, Houston
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The University of Texas Health Science Center at Houston
Houston, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol and Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HSC-DB-17-0313
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.